Viglimet 50+850

Indications

This tablet is prescribed as an addition to diet and exercise to enhance glycemic control in patients diagnosed with type 2 diabetes mellitus. It is particularly beneficial for those whose diabetes is not effectively managed with Metformin Hydrochloride or Vildagliptin alone, or for those already receiving treatment with both medications separately.

Pharmacology

Vildagliptin primarily works by inhibiting DPP-4 (Dipeptidyl peptidase-4), an enzyme responsible for breaking down incretin hormones like GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). By blocking DPP-4, Vildagliptin increases levels of these hormones, which stimulate insulin secretion and reduce glucagon production. This mechanism helps lower hepatic glucose production and thereby decreases blood sugar levels.

Metformin Hydrochloride, a biguanide oral antihyperglycemic, operates through distinct mechanisms from sulfonylureas, enhancing insulin sensitivity and reducing both basal and postprandial plasma glucose levels without inducing hypoglycemia.

Dosage & Administration

For adults, initiate treatment with one tablet in the morning and one in the evening, adjusted based on current Metformin dosage. Patients already taking separate Vildagliptin and Metformin tablets can transition to this combination with equivalent dosing. It is advisable to take this medication with or shortly after meals to minimize potential gastrointestinal side effects associated with Metformin.

Interactions

Clinical studies show no significant pharmacokinetic interactions between Vildagliptin and Metformin Hydrochloride. Vildagliptin’s low potential for drug interactions makes it compatible with a variety of other medications commonly prescribed for diabetes and related conditions.

Contraindications

This combination is contraindicated in patients with known hypersensitivity to Vildagliptin or Metformin Hydrochloride, as well as those with renal dysfunction, acute myocardial infarction, or severe metabolic acidosis. It should be temporarily discontinued in patients undergoing certain radiologic procedures involving contrast materials.

Side Effects

Common side effects may include headache, tremor, dizziness, nausea, and occasional hypoglycemia.

Pregnancy & Lactation

Due to insufficient data, avoid using this combination during pregnancy unless the benefits clearly outweigh potential risks. It is unknown whether Vildagliptin or Metformin Hydrochloride is excreted in human milk; thus, caution is advised for breastfeeding women.

Precautions & Warnings

Patients should be monitored for signs of lactic acidosis, a rare but serious complication of Metformin use. Regular assessment of renal function and liver function tests is recommended, especially in elderly patients and those with pre-existing conditions affecting these organs.

Use in Special Populations

This combination is not recommended for pediatric patients. Elderly patients should have their renal function monitored regularly due to Metformin’s renal excretion. It is also not recommended for patients with significant hepatic impairment.

Therapeutic Class

This medication belongs to the class of combination oral hypoglycemic preparations.

Storage Conditions

Store in a dry place away from light and heat, and keep out of reach of children.